Oura Ring Gen 4 sensor data — not clinical measurementsN=1 case study — not validated for clinical decisionsHEV diagnosed Mar 18; interpret findings cautiously in this Day 21 post-ruxolitinib window

Weekly Tracker

2026-04-01 to 2026-04-07

Generated 2026-04-07 07:19 · Patient 1 — Weekly Tracker

GREEN

On Track

Metrics in normal range

AMBER

Watch

Borderline or declining

RED

Alert

Needs attention

IMPROVING

Normal

Week-over-week

DECLINING

Abnormal

Week-over-week

Doctor Summary — Week of 2026-04-01 to 2026-04-07

ATTENTION: HRV (RMSSD) is declining at 10.0 ms (-11.4% week-over-week)
ATTENTION: Steps is declining at 1327 steps (-58.6% week-over-week)
Temp Deviation improved -25.3% to 0.17 °C
Deep Sleep improved +9.3% to 1.1 h
Sleep Duration declined -8.3% to 5.7 h -- monitor

Metric Details

HRV (RMSSD)

10.0ms

↓ -11.4%Last week: 11.3 ms

Lowest HR

73.5bpm

↔ +2.7%Last week: 71.6 bpm

Average HR

81.0bpm

↔ +0.7%Last week: 80.4 bpm

Sleep Duration

5.7h

↓ -8.3%Last week: 6.2 h

Deep Sleep

1.1h

↑ +9.3%Last week: 1.0 h

REM Sleep

0.9h

↑ +3.3%Last week: 0.9 h

Sleep Efficiency

79%

↔ -0.9%Last week: 79 %

Readiness Score

70pts

↔ -2.0%Last week: 71 pts

Recovery Index

64pts

↔ -0.1%Last week: 64 pts

Steps

1327steps

↓ -58.6%Last week: 3203 steps

Temp Deviation

0.17°C

↑ -25.3%Last week: 0.23 °C

Breath Rate

14.6brpm

↑ +3.7%Last week: 14.1 brpm

Ruxolitinib Progress

Day 22 on ruxolitinib (started 2026-03-16)

Metric	Pre-Rux Baseline	This Week	Change
HRV (RMSSD)	11.7 ms	10.0 ms	↓ -14.6%
Lowest HR	73.0 bpm	73.5 bpm	↑ +0.7%
Average HR	80.5 bpm	81.0 bpm	↑ +0.6%
Sleep Duration	6.0 h	5.7 h	↓ -5.3%
Deep Sleep	1.0 h	1.1 h	↑ +7.2%
REM Sleep	0.8 h	0.9 h	↑ +12.4%
Sleep Efficiency	79 %	79 %	↓ -0.3%
Readiness Score	69 pts	70 pts	↑ +0.7%
Recovery Index	63 pts	64 pts	↑ +2.1%
Steps	2540 steps	1327 steps	↓ -47.8%
Temp Deviation	0.21 °C	0.17 °C	↓ -14.9%
Breath Rate	14.0 brpm	14.6 brpm	↑ +4.5%

All metrics derived from Oura Ring Gen 4 consumer wearable data. Not clinical-grade measurements.

Single-patient case study (N=1). Not validated for clinical decision-making. Not a medical device.

Data: January 08 – April 05, 2026 · Post-intervention: 21 days (ruxolitinib, March 16)